Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2020 08:00 ET | Source: Pfenex, Inc.

Serum Institute of India Private Limited has achieved World Health Organization (WHO) prequalification for PNEUMOSIL®, containing CRM197 produced in Pfenex Expression Technology

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Serum Institute of India Private Limited (Serum Institute) achieved World Health Organization...
December 18, 2019 08:00 ET | Source: Pfenex, Inc.

Pfenex Earns $15 Million Development Milestone Under its Development and License Agreement With Jazz Pharmaceuticals

SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned a $15 million development milestone under its development and license agreement with...
November 20, 2019 16:10 ET | Source: Pfenex, Inc.

Pfenex to Present at the Piper Jaffray 31st Annual Healthcare Conference

SAN DIEGO, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
November 19, 2019 16:10 ET | Source: Pfenex, Inc.

Pfenex to Present at the Evercore ISI HealthCONx Conference 2019

SAN DIEGO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
November 13, 2019 16:40 ET | Source: Pfenex, Inc.

Pfenex Announces Management Change

SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), today announced that Susan Knudson has resigned for personal reasons from her role as Senior Vice President, Chief...
November 07, 2019 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports Third Quarter 2019 Results and Provides Business Update

Received U.S. FDA approval for PF708 to treat osteoporosis and submitted comparative use human factors (HF) study report to FDA; Commercial launch by Alvogen expected upon FDA decision on the...
November 06, 2019 16:10 ET | Source: Pfenex, Inc.

Pfenex to Present at the Jefferies 2019 London Healthcare Conference

SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Jefferies...
October 24, 2019 16:30 ET | Source: Pfenex, Inc.

Pfenex to Announce Third Quarter 2019 Financial Results on November 7th

SAN DIEGO, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to develop...
October 14, 2019 08:00 ET | Source: Pfenex, Inc.

Pfenex Reports Positive Results for PF708 Comparative Use Human Factors Study

Study results found that the FDA-approved PF708 product is noninferior to Forteo® based on a pre-specified statistical analysis of critical patient and caregiver tasks Pfenex believes the study...
October 11, 2019 08:00 ET | Source: Pfenex, Inc.

Pfenex Provides Update for PF708 Outside the United States

New Exclusive Commercialization Agreements in South Korea, Canada, and Israel Submission of Marketing Authorization Application for PF708 in Saudi Arabia Potential approval of PF708 in the EU as...